Genome-wide gene expression analysis reveals pathomechanisms in patients with heart failure and preserved ejection fraction (HFpEF) - Insights from the Leipzig Heart Study

25 May 2019 (00:00 - 00:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Karl-Philipp Rommel

University Medical Centre of the Johannes Gutenberg University, Mainz (Germany)

11 More presentations in this session

Presentation thumbnail

Dual Regulation of SUMO2 and STAT1 by HectD3 Protects Heart from Hypertrophy and Inflammation

Doctor A. Rangrez (Kiel, DE)

Presentation thumbnail

A translational mouse model of HFpEF

Mr A. Withaar (Groningen, NL)

Abstract Slides Video

Presentation thumbnail

Diastolic dysfunction and HFpEF characteristics are exacerbated with ageing in smoothelin-like 1 (SMTNL1)-deficient mice

Ms M. Murali (Calgary, CA)

Abstract Slides Video

Presentation thumbnail

L-2-hydroxyglutarate dehydrogenase (L2HGDH) is a novel metabolic target protecting from cardiac hypertrophy and heart failure

Doctor A. Remes (Kiel, DE)

Abstract Slides Video

Presentation thumbnail

Increased granulocyte neprilysin (CD10) expression is associated with better prognosis in patients with heart failure with reduced ejection fraction

Doctor H. Arfsten (Vienna, AT)

Access the full session

Session thumbnail

Rapid Fire 1 - Basic Science

The Event

Heart Failure 2019

25 May - 28 May 2019

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources